Compare ES & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ES | BIIB |
|---|---|---|
| Founded | 1927 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | ES | BIIB |
|---|---|---|
| Price | $65.95 | $174.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 22 |
| Target Price | $70.83 | ★ $177.40 |
| AVG Volume (30 Days) | 2.7M | ★ 2.7M |
| Earning Date | 02-10-2026 | 02-11-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 3.65 | ★ 10.97 |
| Revenue | ★ $13,148,536,000.00 | $10,065,900,000.00 |
| Revenue This Year | $10.10 | $3.61 |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | $18.42 | ★ $15.93 |
| Revenue Growth | ★ 13.12 | 4.77 |
| 52 Week Low | $52.28 | $110.04 |
| 52 Week High | $75.25 | $185.17 |
| Indicator | ES | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 38.86 | 54.75 |
| Support Level | $66.73 | $168.56 |
| Resistance Level | $68.18 | $175.94 |
| Average True Range (ATR) | 1.23 | 5.10 |
| MACD | 0.14 | -1.52 |
| Stochastic Oscillator | 38.98 | 42.10 |
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).